Next Article in Journal
Metagenomic Studies of Viruses in Weeds and Wild Plants: A Powerful Approach to Characterise Variable Virus Communities
Next Article in Special Issue
Epidemiological and Immunological Features of Obesity and SARS-CoV-2
Previous Article in Journal
Development of a Recombinant RBD Subunit Vaccine for SARS-CoV-2
Brief Report

Prognostic Role of Metabolic Syndrome in COVID-19 Patients: A Systematic Review Meta-Analysis

1
Department of Translational Medicine, Faculty of Medicine, University of Ferrara, 44100 Ferrara, Italy
2
Department of Cardiology, Santa Maria Della Misericordia Hospital, 45100 Rovigo, Italy
3
Division of Cardiology, West Vicenza General Hospitals, Arzignano, 36071 Vicenza, Italy
*
Author to whom correspondence should be addressed.
Academic Editor: Eric Piver
Received: 6 September 2021 / Revised: 17 September 2021 / Accepted: 23 September 2021 / Published: 27 September 2021
(This article belongs to the Special Issue Metabolic Syndrome and COVID-19)
Background: The prevalence and prognostic implications of metabolic syndrome (MetS) in patients infected by the SARS-CoV-2 remain unclear. We performed a systematic review and meta-analysis of prevalence and mortality risk in COVID-19 patients with MetS. Methods: Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed in abstracting data and assessing validity. We searched MEDLINE and Scopus to locate every article published up to 1 September 2021, reporting data on MetS among COVID-19 patients. The pooled prevalence of MetS was calculated using a random effects model and presented using the related 95% confidence interval (CI), while the mortality risk was estimated using the Mantel-Haenszel random effects models with odds ratio (OR) and related 95% CI. Statistical heterogeneity was measured using the Higgins I2 statistic. Results: Six studies, enrolling 209.569 COVID-19 patients [mean age 57.2 years, 114.188 males (54.4%)] met the inclusion criteria and were included in the final analysis. The pooled prevalence of dyslipidaemia was 20.5% of cases (95% CI: 6.7–47.8%, p = 0.03), with high heterogeneity (I2 = 98.9%). Pre-existing MetS was significantly associated with higher risk of short-term mortality (OR: 2.30, 95% CI: 1.52–3.45, p < 0.001), with high heterogeneity (I2 = 89.4%). Meta-regression showed a direct correlation with male gender (p = 0.03), hypertension (p < 0.001), DM (p = 0.01) and hyperlipidaemia (p = 0.04), but no effect when considering age (p = 0.75) and chronic pulmonary disease (p = 0.86) as moderators. Conclusions: MetS represents a major comorbidity in about 20% of COVID-19 patients and it is associated with a 230% increased risk of short-term mortality. View Full-Text
Keywords: metabolic syndrome; COVID-19; prevalence; mortality; dyslipidaemia metabolic syndrome; COVID-19; prevalence; mortality; dyslipidaemia
Show Figures

Figure 1

MDPI and ACS Style

Zuin, M.; Rigatelli, G.; Bilato, C.; Cervellati, C.; Zuliani, G.; Roncon, L. Prognostic Role of Metabolic Syndrome in COVID-19 Patients: A Systematic Review Meta-Analysis. Viruses 2021, 13, 1938. https://0-doi-org.brum.beds.ac.uk/10.3390/v13101938

AMA Style

Zuin M, Rigatelli G, Bilato C, Cervellati C, Zuliani G, Roncon L. Prognostic Role of Metabolic Syndrome in COVID-19 Patients: A Systematic Review Meta-Analysis. Viruses. 2021; 13(10):1938. https://0-doi-org.brum.beds.ac.uk/10.3390/v13101938

Chicago/Turabian Style

Zuin, Marco, Gianluca Rigatelli, Claudio Bilato, Carlo Cervellati, Giovanni Zuliani, and Loris Roncon. 2021. "Prognostic Role of Metabolic Syndrome in COVID-19 Patients: A Systematic Review Meta-Analysis" Viruses 13, no. 10: 1938. https://0-doi-org.brum.beds.ac.uk/10.3390/v13101938

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop